MedTrace Logo

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT07197307 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-29

No results posted yet for this study

Summary

This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.

Conditions

  • Aggressive Diffuse Large B-cell Lymphoma
  • High-grade B-cell Lymphoma (HGBL)
  • Follicular Lymphoma (FL) Grade 3B

Interventions

DRUG

Loncastuximab Tesirine and Epcoritamab

Combination therapy of loncastuximab tesirine and epcoritamab

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Sobi, Inc.

    collaborator INDUSTRY

  • Universität Münster

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2030-01-15
Completion
2030-01-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07197307 on ClinicalTrials.gov